(24/7 MARKET NEWS) – NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”) announced final results, this morning, from a biomarker study conducted to evaluate the potential of NeuroSense’s combination platform therapy for the treatment of Alzheimer’s disease (AD), which showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. NeuroSense expanded the study, based on these encouraging preliminary results, with a larger healthy control group to further validate the results.
NeuroSense Therapeutics is trading at $2.12, up $0.87 (+69.60%), on volume of 6.6 million shares.
Its 52-week range is $1.075 to 8.18. Its setup is favorable to potentially challenging its June and July trading levels.
To view the original NeuroSense Therapeutics content: https://www.prnewswire.com/news-releases/neurosense-therapeutics-reports-positive-final-results-from-alzheimers-biomarker-study-301725883.html
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.